Tirzepatide works on two receptor pathways simultaneously – GLP-1 and GIP. GLP-1 signals fullness and slows digestion. GIP works alongside it to further support appetite and metabolism. Together, they address the underlying biology more comprehensively than either pathway alone.
For many adults, standard approaches to weight management fail because they don’t address the hormonal signals driving hunger. Clinician-guided treatment targeting these pathways may support meaningful, lasting change when diet and exercise alone have not.